SCHEDULE 13D/A: Fresenius KGaA Reduces Stake in Fresenius Medical Care AG to 28.6% Following Share Placement

Fresenius SE & Co. KGaA has reduced its beneficial ownership in Fresenius Medical Care AG to approximately 28.6% after selling 10.6 million shares in an accelerated book building process.

Summary

• Fresenius SE & Co. KGaA (Fresenius KGaA) filed Amendment No. 11 to its Schedule 13D, updating its beneficial ownership in Fresenius Medical Care AG (the Company).
• Following a 'Share Placement' that concluded on March 6, 2025, Fresenius KGaA's beneficial ownership in the Company decreased to 83,780,382 Shares.
• This revised stake represents approximately 28.6% of the Company's outstanding voting shares, calculated based on 293,413,449 Shares outstanding as of February 13, 2025.
• The Share Placement involved the sale of 10.6 million Shares at a price of EUR 44.50 (approximately $46.73 at the pricing) per Share.
• The shares were sold in an unregistered offering, utilizing exemptions from registration under the U.S. Securities Act of 1933.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative for Fresenius Medical Care AG as its major shareholder, Fresenius KGaA, has reduced its stake. While a factual report, the reduction in ownership by a significant shareholder can be perceived by the market as a signal of reduced strategic commitment or a need for capital by the parent, potentially leading to negative market reaction for the issuer.

Negatives

• Fresenius KGaA, a significant long-term shareholder, has reduced its stake in Fresenius Medical Care AG, which could be perceived as a decrease in strategic commitment.
• The sale of 10.6 million shares could introduce additional supply into the market, potentially exerting downward pressure on Fresenius Medical Care AG's stock price.

Risks

• Fresenius KGaA is subject to a 180-day lock-up period, restricting further sales of Shares, with exceptions including an anticipated Exchangeable Bond Offering, which could create uncertainty about future share supply after the lock-up expires.
• The shares were sold in an unregistered offering, which may limit their immediate liquidity or accessibility for certain types of investors.

Future Outlook

Fresenius KGaA anticipates the closing of an Exchangeable Bond Offering on March 11, 2025, which is explicitly noted as an exception to the 180-day lock-up period restricting further sales of Fresenius Medical Care AG shares.

Industry Context

This filing reflects a strategic portfolio adjustment by Fresenius KGaA, a major healthcare conglomerate, as it reduces its ownership stake in Fresenius Medical Care AG. Such divestments are common in mature industries as large holding companies may seek to optimize their asset base, raise capital, or re-focus on core operations, potentially signaling a shift in the long-term strategic relationship between the parent and the subsidiary.

Stakeholder Impact

• Shareholders of Fresenius Medical Care AG: May experience increased share supply and potential downward pressure on the stock price due to the sale by a major holder. The reduction in Fresenius KGaA's stake could also alter perceptions of corporate control and strategic alignment.
• Fresenius KGaA: Benefits from capital raised through the share placement and the upcoming exchangeable bond offering, which can be used for debt reduction, strategic investments, or other corporate purposes.

Next Steps

• Closing of the Exchangeable Bond Offering by Fresenius KGaA, expected on March 11, 2025.
• Expiration of the 180-day lock-up period for Fresenius KGaA regarding further share sales, which commenced on March 4, 2025.

Key Dates

Keywords

Fresenius Medical Care AG, Fresenius SE & Co. KGaA, Schedule 13D, Share Placement, Beneficial Ownership, Equity Stake, SEC Filing, Unregistered Offering, Lock-up Period